Efficacy of an anti-TNF-alpha agent in refractory livedoid vasculopathy: a retrospective analysis

Abstract

Background

Livedoid vasculopathy is a recurrent thrombo-occlusive vasculopathy of cutaneous blood vessels and its standard or first-line therapy is still controversial. Besides hypercoagulability, inflammatory factors may also play a secondary role in the pathogenesis of this disease. Monotherapy of thrombolytics cannot achieve satisfactory results because of concomitant inflammation.

Objective

This pilot study aimed to determine the efficacy of an anti-TNF-alpha agent in patients with refractory livedoid vasculopathy.

Methods

We studied five patients with livedoid vasculopathy who were resistant to steroids, antiplatelets, or danazol therapy, and were treated with etanercept 25–50 mg once a week for 12 consecutive weeks. We assessed clinical characteristics, laboratory findings, and etanercept’s efficacy on skin lesions, pain, and quality of life.

Results

Etanercept therapy resulted in fast relief of pain in a mean time of 2 weeks. The median duration for the disappearance of erythema and ulcer healing was 8.8 weeks and 10.6 weeks, respectively. There was a reduction in pain by 34.3% after 12 consecutive weeks of etanercept treatment. Disease severity and quality of life significantly improved.

Conclusions

In refractory livedoid vasculopathy patients, etanercept therapy is efficient for skin lesions and pain, and improvement of quality of life, especially in rapid relief of pain.

Keywords:

• Livedoid vasculopathy
• atrophie blanche
• etanercept
• quality of life

Disclosure statement

No potential conflict of interest was reported by the author(s).